Age-related differences in the effects of α and γ peroxisome proliferator-activated receptor subtype agonists on endothelial vasodilation in human microvessels

Experimental Gerontology

Volumn 47, Issue 9, 2012, Pages 734-740

  Angulo, Javier ^a   Vallejo, Susana ^b   El Assar, Mariam ^c   García Septiem, Javier ^c   Sánchez Ferrer, Carlos F ^b   Rodríguez Mañas, Leocadio ^c  

^a INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Aging; Cardiovascular risk factors; Endothelial dysfunction; Oxidative stress; PPAR; Superoxide

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; BRADYKININ; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; NITROPRUSSIDE SODIUM; SUPEROXIDE DISMUTASE;

ADULT; AGE DISTRIBUTION; AGING; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FEMALE; HEART FUNCTION; HEART MUSCLE RELAXATION; HUMAN; HUMAN TISSUE; MALE; MICROVASCULATURE; PRIORITY JOURNAL; TREATMENT RESPONSE; VASODILATATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BENZOPHENONES; BUTYRATES; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; MESENTERIC ARTERIES; MICROVESSELS; MIDDLE AGED; OXIDATIVE STRESS; PHENYLUREA COMPOUNDS; PPAR ALPHA; PPAR GAMMA; RISK FACTORS; SUPEROXIDE DISMUTASE; SUPEROXIDES; TYROSINE; VASODILATION;

EID: 84864956001     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2012.06.014     Document Type: Article

References (48)

1. Agrawal B., Kopecky J., Kranzlin B., Rohmeiss P., Pill J., Gretz N. Acute effects of bezafibrate on blood pressure and renal haemodynamics in SHR and WKY rats. Nephrol. Dial. Transplant. 1998, 13:333-339.
2. Barroso I., Gurnell M., Crowley V.E., Agostini M., Schwabe J.W., Soos M.A., Maslen G.L., Williams T.D., Lewis H., Schafer A.J., Chatterjee V.K., O'Rahilly S. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999, 402:880-883.
3. Borghi C., Dormi A., Veronesi M., Sangiorgi Z., Gaddi A. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am. Heart J. 2004, 148:285-292.
4. Brandes R.P., Fleming I., Busse R. Endothelial aging. Cardiovasc. Res. 2005, 66:286-294.
5. Brown K.K., Henke B.R., Blanchard S.G., Cobb J.E., Mook R., Kaldor I., Kliewer S.A., Lehmann J.M., Lenhard J.M., Harrington W.W., Novak P.J., Faison W., Binz J.G., Hashim M.A., Oliver W.O., Brown H.R., Parks D.J., Plunket K.D., Tong W.Q., Menius J.A., Adkison K., Noble S.A., Willson T.M. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 1999, 48:1415-1424.
6. Brown P.J., Stuart L.W., Hurley K.P., Lewis M.C., Winegar D.A., Wilson J.G., Wilkison W.O., Ittoop O.R., Willson T.M. Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. Bioorg. Med. Chem. Lett. 2001, 11:1225-1227.
7. Campia U., Matuskey L.A., Panza J.A. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006, 113:867-875.
8. Celermajer D.S., Sorensen K.E., Spiegelhalter D.J., Georgakopoulos D., Robinson J., Deanfield J.E. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J. Am. Coll. Cardiol. 1994, 24:471-476.
9. Chew G.T., Watts G.F., Davis T.M., Stuckey B.G., Beilin L.J., Thompson P.L., Burke V., Currie P.J. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care 2008, 31:1502-1509.
10. DeSouza C.A., Clevenger C.M., Greiner J.J., Smith D.T., Hoetzer G.L., Shapiro L.F., Stauffer B.L. Evidence for agonist-specific endothelial vasodilator dysfunction with ageing in healthy humans. J. Physiol. 2002, 542:255-262.
11. Donato A.J., Eskurza I., Silver A.E., Levy A.S., Pierce G.L., Gates P.E., Seals D.R. Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endothelium-dependent dilation and upregulation of nuclear factor-kappaB. Circ. Res. 2007, 100:1659-1666.
12. Eskurza I., Monahan K.D., Robinson J.A., Seals D.R. Effect of acute and chronic ascorbic acid on flow-mediated dilatation with sedentary and physically active human ageing. J. Physiol. 2004, 556:315-324.
13. Eskurza I., Kahn Z.D., Seals D.R. Xanthine oxidase does not contribute to impaired peripheral conduit artery endothelium-dependent dilatation with ageing. J. Physiol. 2006, 571:661-668.
14. Fujishima S., Ohya Y., Nakamura Y., Onaka U., Abe I., Fujishima M. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. Am. J. Hypertens. 1998, 11:1134-1137.
15. Gelinas D.S., McLaurin J. PPAR-alpha expression inversely correlates with inflammatory cytokines IL-1beta and TNF-alpha in aging rats. Neurochem. Res. 2005, 30:1369-1375.
16. Gerhard M., Roddy M.A., Creager S.J., Creager M.A. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension 1996, 27:849-853.
17. Haak T., Haak E., Kusterer K., Weber A., Kohleisen M., Usadel K.H. Fenofibrate improves microcirculation in patients with hyperlipidemia. Eur. J. Med. Res. 1998, 3:50-54.
18. Halabi C.M., Beyer A.M., de Lange W.J., Keen H.L., Baumbach G.L., Faraci F.M., Sigmund C.D. Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell. Metab. 2008, 7:215-226.
19. Hamblin M., Chang L., Fan Y., Zhang J., Chen Y.E. PPARs and the cardiovascular system. Antioxid. Redox Signal. 2009, 11:1415-1452.
20. Hatake K., Kakishita E., Wakabayashi I., Sakiyama N., Hishida S. Effect of aging on endothelium-dependent vascular relaxation of isolated human basilar artery to thrombin and bradykinin. Stroke 1990, 21:1039-1043.
21. Hayflick L. Biological aging is no longer an unsolved problem. Ann. N. Y. Acad. Sci. 2007, 1100:1-13.
22. Higashi Y., Sasaki S., Nakagawa K., Kimura M., Noma K., Hara K., Jitsuiki D., Goto C., Oshima T., Chayama K., Yoshizumi M. Tetrahydrobiopterin improves aging-related impairment of endothelium-dependent vasodilation through increase in nitric oxide production. Atherosclerosis 2006, 186:390-395.
23. Hwang J., Kleinhenz D.J., Lassegue B., Griendling K.K., Dikalov S., Hart C.M. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am. J. Physiol. Cell Physiol. 2005, 288:C899-C905.
24. Hwang J., Kleinhenz D.J., Rupnow H.L., Campbell A.G., Thule P.M., Sutliff R.L., Hart C.M. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice. Vascul. Pharmacol. 2007, 46:456-462.
25. Inoue I., Goto S., Matsunaga T., Nakajima T., Awata T., Hokari S., Komoda T., Katayama S. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 2001, 50:3-11.
26. Jian B., Yang S., Chen D., Zou L., Chatham J.C., Chaudry I., Raju R. Aging influences cardiac mitochondrial gene expression and cardiovascular function following hemorrhage injury. Mol. Med. 2011, 17:542-549.
27. Kim J.I., Tsujino T., Fujioka Y., Saito K., Yokoyama M. Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertens. Res. 2003, 26:307-313.
28. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: PART I: aging arteries: a "set up" for vascular disease. Circulation 2003, 107:139-146.
29. Mulvany M.J., Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ. Res. 1977, 41:19-26.
30. Najjar S.S., Scuteri A., Lakatta E.G. Arterial aging: is it an immutable cardiovascular risk factor?. Hypertension 2005, 46:454-462.
31. Olukman M., Sezer E.D., Ulker S., Sozmen E.Y., Cinar G.M. Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats. Exp. Diabetes Res. 2010, 2010:828531.
32. Pepe S., Lakatta E.G. Aging hearts and vessels: masters of adaptation and survival. Cardiovasc. Res. 2005, 66:190-193.
33. Phelps L.E., Peuler J.D. Evidence of direct smooth muscle relaxant effects of the fibrate gemfibrozil. J. Smooth Muscle Res. 2010, 46:125-142.
34. Pistrosch F., Passauer J., Fischer S., Fuecker K., Hanefeld M., Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004, 27:484-490.
35. Rodríguez-Mañas L., Sánchez-Rodríguez C., Vallejo S., El-Assar M., Peiro C., Azcutia V., Matesanz N., Sánchez-Ferrer C.F., Nevado J. Pro-inflammatory effects of early non-enzymatic glycated proteins in human mesothelial cells vary with cell donor's age. Br. J. Pharmacol. 2006, 149:979-987.
36. Rodriguez-Mañas L., El-Assar M., Vallejo S., Lopez-Doriga P., Solis J., Petidier R., Montes M., Nevado J., Castro M., Gómez-Guerrero C., Peiró C., Sánchez-Ferrer C.F. Endothelial dysfunction in aged humans is related with oxidative stress and vascular inflammation. Aging Cell 2009, 8:226-238.
37. Scuteri, A., Lakatta, E.G., 2012. Bringing prevention in geriatrics: Evidences from cardiovascular medicine supporting the new challenge. Exp. Gerontol http://dx.doi.org/10.1016/j.bbr.2011.03.031.
38. Scuteri A., Tesauro M., Rizza S., Iantorno M., Federici M., Lauro D., Campia U., Turriziani M., Fusco A., Cocciolillo G., Lauro R. Endothelial function and arterial stiffness in normotensive normoglycemic first-degree relatives of diabetic patients are independent of the metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. 2008, 18:349-356.
39. Seals D.R., Moreau K.L., Gates P.E., Eskurza I. Modulatory influences on ageing of the vasculature in healthy humans. Exp. Gerontol. 2006, 41:501-507.
40. Sengupta S., Peterson T.R., Laplante M., Oh S., Sabatini D.M. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature 2010, 468:1100-1104.
41. Taddei S., Virdis A., Mattei P., Ghiadoni L., Gennari A., Fasolo C.B., Sudano I., Salvetti A. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995, 91:1981-1987.
42. Taddei S., Virdis A., Ghiadoni L., Versari D., Salvetti A. Endothelium, aging, and hypertension. Curr. Hypertens. Rep. 2006, 8:84-89.
43. Tao L., Liu H.R., Gao E., Teng Z.P., Lopez B.L., Christopher T.A., Ma X.L., Batinic-Haberle I., Willette R.N., Ohlstein E.H., Yue T.L. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 2003, 108:2805-2811.
44. Urakami-Harasawa L., Shimokawa H., Nakashima M., Egashira K., Takeshita A. Importance of endothelium-derived hyperpolarizing factor in human arteries. J. Clin. Invest. 1997, 100:2793-2799.
45. Wang G., Liu X., Guo Q., Namura S. Chronic treatment with fibrates elevates superoxide dismutase in adult mouse brain microvessels. Brain Res. 2010, 1359:247-255.
46. Wiel E., Lebuffe G., Robin E., Gasan G., Corseaux D., Tavernier B., Jude B., Bordet R., Vallet B. Pretreatment with peroxysome proliferator-activated receptor alpha agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock. Intensive Care Med. 2005, 31:1269-1279.
47. Williams J.M., Zhao X., Wang M.H., Imig J.D., Pollock D.M. Peroxisome proliferator-activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. Hypertension 2005, 46:366-371.
48. Yu J., Zhang Z., Li Z., Feng X., He L., Liu S., Mao J., Wang G., Wang X. Peroxisome proliferator-activated receptor-gamma(PPARgamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease. J. Int. Med. Res. 2010, 38:86-94.